{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-26-000003","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.292783+00:00","generated_at":"2026-05-16T10:51:11.422752+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akebia expects Q4 2025 Vafseo net revenue $5-6M; dosed first patient in praliciguat Phase 2","bullets":["Vafseo Q4 net product revenue expected $5-6M (vs. underlying dosing demand $10.5-11.5M) due to $4.5-5M inventory adjustment at USRC.","Total Q4 prescribers ~785 (+8% QoQ); at least 25% of new patients from non-USRC centers (up from <10% Q3).","First patient dosed in praliciguat Phase 2 trial for FSGS; AKB-097 basket study starts H2 2026.","VOICE Phase IV fully enrolled (2,100+ patients); topline early 2027; VOCAL trial data expected Q4 2026.","Revenue growth expected to resume Q1 2026; broad prescribing access to ~275,000 dialysis patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-26-000003","json":"https://secwatch.observer/filing/0001517022-26-000003.json","markdown":"https://secwatch.observer/filing/0001517022-26-000003.md","text":"https://secwatch.observer/filing/0001517022-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000003/0001517022-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000003/akba-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:51:11.422752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}